- Home
- GRNQ vs KZIA Comparison
GRNQ vs KZIA Comparison
Compare GRNQ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNQ
- KZIA
- Stock Information
- Founded
- GRNQ 2013
- KZIA 1994
- Country
- GRNQ Malaysia
- KZIA Australia
- Employees
- GRNQ N/A
- KZIA N/A
- Industry
- GRNQ EDP Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- GRNQ Technology
- KZIA Health Care
- Exchange
- GRNQ Nasdaq
- KZIA Nasdaq
- Market Cap
- GRNQ 11.3M
- KZIA 11.7M
- IPO Year
- GRNQ 2018
- KZIA 1999
- Fundamental
- Price
- GRNQ $1.43
- KZIA $7.69
- Analyst Decision
- GRNQ
- KZIA Strong Buy
- Analyst Count
- GRNQ 0
- KZIA 3
- Target Price
- GRNQ N/A
- KZIA $16.00
- AVG Volume (30 Days)
- GRNQ 823.9K
- KZIA 95.0K
- Earning Date
- GRNQ 11-13-2025
- KZIA 11-14-2025
- Dividend Yield
- GRNQ N/A
- KZIA N/A
- EPS Growth
- GRNQ N/A
- KZIA N/A
- EPS
- GRNQ N/A
- KZIA N/A
- Revenue
- GRNQ $3,256,679.00
- KZIA $1,549,158.00
- Revenue This Year
- GRNQ N/A
- KZIA N/A
- Revenue Next Year
- GRNQ N/A
- KZIA N/A
- P/E Ratio
- GRNQ N/A
- KZIA N/A
- Revenue Growth
- GRNQ N/A
- KZIA 248983.08
- 52 Week Low
- GRNQ $0.80
- KZIA $2.86
- 52 Week High
- GRNQ $2.50
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- GRNQ 51.35
- KZIA 57.79
- Support Level
- GRNQ $1.25
- KZIA $6.51
- Resistance Level
- GRNQ $1.48
- KZIA $7.39
- Average True Range (ATR)
- GRNQ 0.09
- KZIA 0.44
- MACD
- GRNQ 0.00
- KZIA 0.10
- Stochastic Oscillator
- GRNQ 77.38
- KZIA 81.25
About GRNQ Greenpro Capital Corp.
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.